All

Vedanta Biosciences Announces the Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection Will Continue as Planned Following Protocol-Specified Interim Analysis
2 April 2026

Vedanta Biosciences Announces the Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection Will Continue as Planned Following Protocol-Specified Interim Analysis

Vedanta Biosciences, a late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal diseases, today announced that the...

Read more
Standing Ovation raises $34.2 million to scale up its breakthrough technology for producing dairy proteins through precision fermentation, offering a sovereign and sustainable response to the surge in global demand for protein
31 March 2026

Standing Ovation raises $34.2 million to scale up its breakthrough technology for producing dairy proteins through precision fermentation, offering a sovereign and sustainable response to the surge in global demand for protein

Paris, 31 March 2026 - Standing Ovation, a French precision fermentation pioneer producing next-
generation proteins, has announced a $34.2 million (€30 million) Series...

Read the press release
SumUp and Upvest launch in-app investing for merchants
24 March 2026

SumUp and Upvest launch in-app investing for merchants

SumUp has partnered with Upvest to integrate money market fund investing into its business banking platform for merchants.

Read more
MaaT Pharma Presents the ARES Phase 3 Pivotal Trial Final Data During the Presidential Plenary Session at the 52nd Annual Meeting of the European Society for Bone and Marrow Transplantation
23 March 2026

MaaT Pharma Presents the ARES Phase 3 Pivotal Trial Final Data During the Presidential Plenary Session at the 52nd Annual Meeting of the European Society for Bone and Marrow Transplantation

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated...

Read more
Citalid Secures U.S. Patent for Automated Cyberattack Simulation Powering Its CRQ Platform
17 March 2026

Citalid Secures U.S. Patent for Automated Cyberattack Simulation Powering Its CRQ Platform

Citalid, the leading cyber risk quantification (CRQ) tech provider in Europe, today announced the grant of U.S. Patent No. 12,542,803 B2 for a proprietary automated cyberattack...

Read more
IDnow adopts AI‑powered contact center platform to handle growing IDV volumes
9 March 2026

IDnow adopts AI‑powered contact center platform to handle growing IDV volumes

Identity verification provider IDnow has selected Bright Pattern’s AI‑driven contact center platform to support more than one million video‑based identifications per...

Read more
TransferGo enters new stage of growth: Bank of Lithuania expands company’s EMI license
19 February 2026

TransferGo enters new stage of growth: Bank of Lithuania expands company’s EMI license

The Bank of Lithuania has supplemented the electronic money institution (EMI) license for the fintech company Ltd TransferGo Lithuania. This enhancement enables the company to...

Read more
Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis
11 February 2026

Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis

Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces positive...

Read more